Strides Arcolab’s subsidiary receives European approval for its Oral Dosage Oncology facility

01 Jul 2011 Evaluate

Onco Therapies, a division of Agila, which is a wholly owned subsidiary of Strides Arcolab, has received European approval for its Oral Dosage Oncology facility (tablet and hard gelatine capsules) in Bangalore. The injectable facility within the Oncology complex has already been approved by all major regulatory agencies. Thus, the facility is now amongst a few European approved Oral Dosage oncology plants worldwide.

Further, the company expects to commercialize 2 products in Europe during Q3 2011. The state of art Oncology complex which was established in 2009 manufactures injectables, oral products (tablets and soft gels) in the oncology domain. It has been built to the most exacting standards, meeting the requirements of the regulatory authorities in the most stringent global markets and is already approved by all the major regulatory authorities following the company to sell off globally.

Agila is the specialties unit of Strides Arcolab which was spun off as a separate division post the company’s restricting in 2009. It is focused on key domains such as oncologyistics,  penems, pencillins, cephalosphrins, opthalmics, peptides and biosimilars and operates  from 8  world class global  manufacturing facilities, including one of the largest  steriles capacity in India and amongst the  largest lyophilizations  capacities in the world.

Strides Pharma Scien Share Price

684.30 -15.00 (-2.15%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.